Clinical and Experimental Nephrology

, Volume 17, Issue 1, pp 10–15 | Cite as

New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy

  • Mitsuyoshi Namba
  • Tomoyuki Katsuno
  • Yoshiki Kusunoki
  • Toshihiro Matsuo
  • Masayuki Miuchi
  • Jun-ichiro Miyagawa
Review Article

Abstract

Incretin-based therapy was first made available for the treatment of type 2 diabetes mellitus (T2DM) in the US in 2006 and in Japan in 2009. Four DPP-4 inhibitors and two GLP-1 analog/receptor agonists are currently available. The effects of incretin-based therapy are assumed to be exerted mainly through the hormonal and neuronal actions of one of the incretins, GLP-1, which is secreted from L cells localized in the small intestine. The benefits of this therapy over conventional sulfonylureas or insulin injections, such as fewer hypoglycemic events and reduced body weight gain, derive from the glucose-dependent insulinotropic effect. The protective effects of this therapy on vulnerable pancreatic β-cells and against micro/macroangiopathy in T2DM are also most welcome. Indications and/or contraindications for incretin-based therapy should be clarified by prospectively studying the experiences of Japanese T2DM patients undergoing this therapy in the clinical setting.

Keywords

Incretin GLP-1 GIP DPP-4 inhibitors GLP-1 analog/receptor agonists 

References

  1. 1.
    The Japan Society of Dialysis Therapy. http://docs.jsdt.or.jp/overview/pdf2012/p15.pdf.
  2. 2.
    Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen M-R, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance—lessons from the Botnia study. Diabetes. 2000;49:975–80.PubMedCrossRefGoogle Scholar
  3. 3.
    Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004;66S:S37–43.CrossRefGoogle Scholar
  4. 4.
    Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122:4–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Miuchi M, Miyagawa J-I, Konishi K, Nagai E, Matsuo T, Murai K, Katsuno T, Hamaguchi T Namba M. Morphologic changes of α-cells in the pancreas of Japanese non-obese type 2 diabetes (oral presentation). In: 3rd Scientific Meeting of the Asian Association for the Study of Diabetes. Tokyo: AASD; 2011.Google Scholar
  6. 6.
    Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31:233–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornimal I, Shen YT, Shannon RP. Direct effcts of glucagon-like peptide-1 on myocardial contractlity and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317:1106–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Effects of glucagon-like peptide-1 on endotherail function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209–15.PubMedCrossRefGoogle Scholar
  9. 9.
    van Poppel PC, Netea MG, Smith P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilation in type 2 diabetes. Diabetes Care. 2011;34:2072–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002;302:881–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makinjo H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54:965–78.Google Scholar
  12. 12.
    Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi S. Glucago-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism. 2011;60:1271–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Katsuno T, Kusunoki Y, Tokuda M, Murai K, Ochi F, Miuchi M, Hamaguchi T, Miyagawa J-i Namba M. Strict glycemic control in Japanese type 2 diabetes patients with incretin-based therapy—efficacy of continuous glucose monitoring for the secure transition and fine tuning. Infusyst Asia. 2012;7(1):6–8.Google Scholar
  14. 14.
    Blech S, Ludwig-Scwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38:667–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor sitagliptin in humans. Drug Metab Dispos. 2007;35:533–8.PubMedCrossRefGoogle Scholar
  16. 16.
    He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D. Absorption, metabolism and excretion of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009;37:536–44.PubMedCrossRefGoogle Scholar
  17. 17.
    Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A. Pharmacokinetics, pharmacodymamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30:513–27.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2012

Authors and Affiliations

  • Mitsuyoshi Namba
    • 1
  • Tomoyuki Katsuno
    • 1
  • Yoshiki Kusunoki
    • 1
  • Toshihiro Matsuo
    • 1
  • Masayuki Miuchi
    • 1
  • Jun-ichiro Miyagawa
    • 1
  1. 1.Division of Diabetes and Metabolism, Department of Internal MedicineHyogo College of MedicineNishinomiyaJapan

Personalised recommendations